What is the recommended dosing and administration of Sevelamer 800‑mg tablets for a dialysis patient with hyperphosphatemia?

Sevelamer 800 mg Dosing and Administration for Dialysis Patients with Hyperphosphatemia

For dialysis patients not previously on a phosphate binder, start sevelamer 800 mg at 1-2 tablets three times daily with meals (total 2.4-4.8 g/day) based on baseline serum phosphorus, then titrate by one tablet per meal every 2 weeks to achieve target phosphorus of 3.5-5.5 mg/dL. 1

Initial Dosing Algorithm

The FDA-approved starting dose depends on your patient's baseline serum phosphorus 1:

• Phosphorus 5.5-7.5 mg/dL: Start 800 mg (1 tablet) three times daily with meals
• Phosphorus 7.5-9.0 mg/dL: Start 1600 mg (2 tablets) three times daily with meals
• Phosphorus ≥9.0 mg/dL: Start 1600 mg (2 tablets) three times daily with meals

Switching from Calcium Acetate

If transitioning from calcium acetate, use approximately mg-for-mg equivalent dosing 1:

• 1 calcium acetate tablet per meal → 1 sevelamer 800 mg tablet per meal
• 2 calcium acetate tablets per meal → 2 sevelamer 800 mg tablets per meal
• 3 calcium acetate tablets per meal → 3 sevelamer 800 mg tablets per meal

Dose Titration Strategy

Adjust every 2 weeks based on serum phosphorus 1:

• >5.5 mg/dL: Increase by 1 tablet per meal
• 3.5-5.5 mg/dL: Maintain current dose (target achieved)
• <3.5 mg/dL: Decrease by 1 tablet per meal

The average effective dose in clinical trials was approximately three 800 mg tablets per meal (7.2 g/day total), with maximum studied doses up to 13 g/day 1.

Clinical Context and Guideline Framework

Sevelamer is particularly preferred in specific dialysis patient populations 2:

When to Prioritize Sevelamer Over Calcium-Based Binders:

1. Hypercalcemia (corrected calcium >10.2 mg/dL) 2
2. Low PTH (<150 pg/mL on 2 consecutive measurements) 2
3. Severe vascular or soft-tissue calcifications 2
4. When calcium-based binder dose would exceed 1,500 mg elemental calcium/day 2

The K/DOQI guidelines establish that both calcium-based and non-calcium phosphate binders like sevelamer are effective and either may be used as primary therapy in Stage 5 CKD 2. However, the 2018 KDIGO update emphasizes restricting calcium-based binder doses, strengthening the role for sevelamer 3.

Administration Pearls

• Take with meals (10-15 minutes before or during) to maximize phosphate binding 2
• Swallow tablets whole per FDA labeling 1
• Separate from other medications when drug interactions are expected (particularly ciprofloxacin and mycophenolate) 1

Important Caveat on Tablet Crushing

While the FDA label recommends swallowing tablets whole 1, one retrospective study found that crushing sevelamer tablets for enteral feeding tube administration resulted in similar tube obstruction rates (0.4%) compared to packets (0.5%) 4. However, this practice requires clear preparation protocols and should be reserved for situations where packets are unavailable or cost-prohibitive.

Monitoring Parameters

• Serum phosphorus: Monthly initially, then per clinical need 2
• Target phosphorus for dialysis patients: 3.5-5.5 mg/dL 2
• Serum calcium: Maintain 8.4-9.5 mg/dL (lower end of normal) 2
• Calcium-phosphorus product: Keep <55 mg²/dL² 5

Common Pitfalls to Avoid

1. Inadequate initial dosing: Starting too low delays phosphorus control. Use the FDA algorithm based on baseline phosphorus 1

2. Insufficient titration: The average effective dose is ~7 g/day, not the starting dose of 2.4 g/day 1, 6

3. Premature discontinuation: GI side effects are the most common reason for stopping treatment 1. Gradual titration from lower starting doses improves tolerability 6

4. Ignoring pill burden: Sevelamer requires multiple large tablets with each meal. This significantly impacts adherence and quality of life 7. Address this proactively with patient education and consider intensified dialysis if phosphorus control remains inadequate despite reasonable attempts 7

5. Drug interactions: Sevelamer binds ciprofloxacin and mycophenolate in the GI tract—dose these medications at least 2 hours before or after sevelamer 1

Evidence for Cardiovascular Benefits

Beyond phosphorus control, sevelamer offers advantages over calcium-based binders. The Treat-to-Goal study demonstrated less progression of coronary and aortic calcification with sevelamer versus calcium-based binders 2, 5. Sevelamer also reduces LDL cholesterol by approximately 30% 2, 7, though the independent contribution of this effect to cardiovascular outcomes remains uncertain.